Xtl Biopharmaceuticals (XTLB) Total Current Liabilities (2009 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Total Current Liabilities of $420000.0 for Q4 2025, down 80.97% year-on-year from $2.2 million in Q4 2024, and down 80.97% on a QoQ basis from $2.2 million in Q4 2024.
Xtl Biopharmaceuticals (XTLB) Total Current Liabilities (2009 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Total Current Liabilities for 14 consecutive years, with $420000.0 the latest figure, recorded in Q4 2025.
- Quarterly Total Current Liabilities fell 80.97% year-over-year to $420000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $420000.0 (down 80.97% YoY) and the FY2025 annual result came in at $420000.0, down 80.97% from the prior year.
- Total Current Liabilities fell to $420000.0 in Q4 2025 per XTLB's latest filing, from $2.2 million in the prior quarter.
- Over the last five years, Total Current Liabilities for XTLB reached as high as $2.2 million in Q4 2024 and fell as low as $185000.0 in Q3 2021.
- A 5-year average of $537142.9 and a median of $251000.0 in 2021 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities soared 971.36% — and 2025, when it tumbled 80.97%.
- Year by year, Total Current Liabilities stood at $231000.0 in 2021, then advanced by 12.55% to $260000.0 in 2022, then slipped by 20.77% to $206000.0 in 2023, then surged by 971.36% to $2.2 million in 2024, then slumped by 80.97% to $420000.0 in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $420000.0, $2.2 million, and $206000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 289.60 Mn |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | 420,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 420,000.00 |
| Dec 31, 2024 | 2.21 Mn |
| Dec 31, 2023 | 206,000.00 |
| Mar 31, 2022 | 260,000.00 |
| Dec 31, 2021 | 231,000.00 |
| Sep 30, 2021 | 185,000.00 |
| Mar 31, 2021 | 251,000.00 |
| Dec 31, 2020 | 254,000.00 |
| Sep 30, 2020 | 182,000.00 |
| Jun 30, 2020 | 194,000.00 |
| Mar 31, 2020 | 244,000.00 |
| Dec 31, 2019 | 232,000.00 |
| Sep 30, 2019 | 200,000.00 |
| Jun 30, 2019 | 203,000.00 |
| Mar 31, 2019 | 236,000.00 |
| Dec 31, 2018 | 253,000.00 |
| Sep 30, 2018 | 197,000.00 |
| Jun 30, 2018 | 198,000.00 |
| Mar 31, 2018 | 232,000.00 |
| Dec 31, 2017 | 300,000.00 |